NZ596615A - Substituted isoquinoline derivative - Google Patents

Substituted isoquinoline derivative

Info

Publication number
NZ596615A
NZ596615A NZ596615A NZ59661510A NZ596615A NZ 596615 A NZ596615 A NZ 596615A NZ 596615 A NZ596615 A NZ 596615A NZ 59661510 A NZ59661510 A NZ 59661510A NZ 596615 A NZ596615 A NZ 596615A
Authority
NZ
New Zealand
Prior art keywords
independently represent
derivative
group
isoquinoline
salt
Prior art date
Application number
NZ596615A
Other languages
English (en)
Inventor
Hiroyoshi Hidaka
Kouichi Takahashi
Yoshihiro Inoue
Kengo Sumi
Ryohei Nakamura
Original Assignee
Western Therapeutics Inst Inc D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Therapeutics Inst Inc D filed Critical Western Therapeutics Inst Inc D
Publication of NZ596615A publication Critical patent/NZ596615A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
NZ596615A 2009-06-19 2010-06-18 Substituted isoquinoline derivative NZ596615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009146040 2009-06-19
PCT/JP2010/004101 WO2010146881A1 (ja) 2009-06-19 2010-06-18 置換されたイソキノリン誘導体

Publications (1)

Publication Number Publication Date
NZ596615A true NZ596615A (en) 2013-07-26

Family

ID=43356211

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596615A NZ596615A (en) 2009-06-19 2010-06-18 Substituted isoquinoline derivative

Country Status (19)

Country Link
US (1) US8951997B2 (xx)
EP (1) EP2444395B1 (xx)
JP (1) JP4915010B2 (xx)
KR (1) KR101732907B1 (xx)
CN (1) CN102448941B (xx)
AU (1) AU2010261206B2 (xx)
BR (1) BRPI1011683B8 (xx)
CA (1) CA2764124C (xx)
CY (1) CY1117157T1 (xx)
DK (1) DK2444395T3 (xx)
EA (1) EA019523B1 (xx)
ES (1) ES2560603T3 (xx)
HR (1) HRP20160096T1 (xx)
HU (1) HUE028684T2 (xx)
MX (1) MX2011013857A (xx)
NZ (1) NZ596615A (xx)
PL (1) PL2444395T3 (xx)
TW (1) TWI527798B (xx)
WO (1) WO2010146881A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
ES2672624T3 (es) 2009-05-01 2018-06-15 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedades
KR101911324B1 (ko) 2010-12-22 2018-10-25 가부시키가이샤 디. 웨스턴 세라퓨틱스 겡큐쇼 신규한 치환 이소퀴놀린 유도체
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
EP3626245B1 (en) * 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
CN105906609A (zh) * 2016-05-19 2016-08-31 武昌理工学院 一种1,4-二氮杂环庚烷衍生物的制备方法
JP7032814B2 (ja) 2016-08-31 2022-03-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド オキソピコリンアミド誘導体、その製造方法およびその医薬用途
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
US9840468B1 (en) 2016-12-30 2017-12-12 Aerie Pharmaceuticals, Inc. Methods for the preparation of 6-aminoisoquinoline
SG11201908179UA (en) 2017-03-31 2019-10-30 Aerie Pharmaceuticals Inc Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109134433B (zh) * 2017-06-16 2021-05-25 成都先导药物开发股份有限公司 一种抑制rock的化合物及其应用
CN108929270B (zh) * 2018-08-15 2021-06-08 上海罕道医药科技有限公司 一种药物中间体双取代含氮杂环的胺类化合物的合成
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP3875449A4 (en) * 2018-11-01 2022-07-06 D. Western Therapeutics Institute, Inc. 1,4-DIAZOCANE COMPOUND OR SALT THEREOF
CN113194949A (zh) * 2018-12-18 2021-07-30 株式会社D.西医疗法研究所 异喹啉磺酰氯酸加成盐和其制造方法
WO2022047315A1 (en) * 2020-08-31 2022-03-03 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0667926B2 (ja) 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH0215067A (ja) 1988-07-04 1990-01-18 Hokuriku Seiyaku Co Ltd イソキノリンスルホンアミド誘導体
US5216150A (en) 1988-12-26 1993-06-01 Hiroyoshi Hidaka Derivatives of isoquinoline (and naphthalene) sulfonamides
US5245034A (en) 1988-12-26 1993-09-14 Kiroyoshi Hidaka Compound having vessel smooth muscle relaxation activity
JPH069402A (ja) 1991-05-15 1994-01-18 Hiroyoshi Hidaka 抗潰瘍剤
AU1557497A (en) 1996-02-02 1997-08-22 Nippon Shinyaku Co. Ltd. Isoquinoline derivatives and drugs
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP1720874A4 (en) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. 4-ブロモイソキノリン誘導体及びこれを含有する医薬
DE602006005351D1 (de) 2005-04-25 2009-04-09 Western Therapeutics Inst Inc Hochselektiver rho-kinase-inhibitor
WO2007026664A1 (ja) 2005-08-30 2007-03-08 Asahi Kasei Pharma Corporation スルホンアミド化合物
US20080064681A1 (en) * 2006-09-11 2008-03-13 Hiroyoshi Hidaka Therapeutic agent for treating glaucoma
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
KR20090103903A (ko) 2006-12-27 2009-10-01 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative

Also Published As

Publication number Publication date
CY1117157T1 (el) 2017-04-05
WO2010146881A1 (ja) 2010-12-23
EP2444395A4 (en) 2012-11-28
PL2444395T3 (pl) 2016-06-30
CN102448941B (zh) 2016-04-06
MX2011013857A (es) 2012-01-30
ES2560603T3 (es) 2016-02-22
AU2010261206B2 (en) 2015-10-08
EP2444395B1 (en) 2016-01-06
AU2010261206A1 (en) 2011-12-15
EA019523B1 (ru) 2014-04-30
BRPI1011683A2 (pt) 2016-03-22
HUE028684T2 (en) 2016-12-28
TW201100385A (en) 2011-01-01
EA201171328A1 (ru) 2012-05-30
KR101732907B1 (ko) 2017-05-08
CN102448941A (zh) 2012-05-09
BRPI1011683B8 (pt) 2021-05-25
US20120035159A1 (en) 2012-02-09
TWI527798B (zh) 2016-04-01
JPWO2010146881A1 (ja) 2012-12-06
HRP20160096T1 (hr) 2016-02-26
DK2444395T3 (en) 2016-03-14
JP4915010B2 (ja) 2012-04-11
EP2444395A1 (en) 2012-04-25
CA2764124C (en) 2016-12-13
US8951997B2 (en) 2015-02-10
KR20120069609A (ko) 2012-06-28
CA2764124A1 (en) 2010-12-23
BRPI1011683B1 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
NZ596615A (en) Substituted isoquinoline derivative
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
MY153910A (en) BICYCLIC y-AMINO ACID DERIVATIVE
MY138941A (en) Aryl-pyridine derivatives
MX2009002802A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparacion y su aplicacion en terapeutica.
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
EA201591000A1 (ru) Пирролобензодиазепины
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TW200621786A (en) Condensed pyrazole derivatives, their preparation and application in therapeutics
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW201129564A (en) Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof
MX2011009423A (es) Compuesto de piperazina capaz de inhibir prostaglandina d sintasa.
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
WO2008136444A1 (ja) 縮合複素環誘導体
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
MY155661A (en) Novel 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof
MY183326A (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
MX2013007296A (es) Derivado novedoso de isoquinolina sustituido.
TW200714593A (en) Agent for treatment of solid tumor
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
TW200720265A (en) Agent for treatment of hematopoietic tumor
MX2012008055A (es) Agente profilactico o de mejoramiento para la pigmentacion.
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
MX2009010225A (es) Nuevos compuestos 707 y sus usos.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUN 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20140527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20170619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2019 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20190523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2021 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20200518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2022 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20210520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 JUN 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230605